Hercules, CA — June 19, 2014 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of its S3™ Biosafety System Class I, an intelligent aerosol containment hood designed for Bio-Rad’s S3™ Cell Sorter. The system adheres to the biosafety requirements of the International Society for Advancement of Cytometry (ISAC) and protects users and the environment from aerosols created during the cell sorting process.
The S3 Biosafety System Class I encloses the S3 Cell Sorter on the benchtop, providing an alternative to the large and expensive biosafety hoods traditionally used with cell sorters.
Additional benefits of the S3 Biosafety System Class I include:
- Software control — integrates with Bio-Rad’s S3™ ProSort™ Software, which provides real-time information about biosafety system status, system temperature, and HEPA filter life
- Fully accessible — offers easy access to the S3 Cell Sorter for cleaning and maintenance via vinyl walls that are magnetically attached to the aluminum biosafety system frame
- Quiet and energy efficient — generates low vibration and sound levels while specialized fans and low backpressure from the HEPA filter reduce energy usage
For more information about Bio-Rad’s S3 Cell Sorter, please visit www.bio-rad.com/cellsorter.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) designs, manufactures, and distributes a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs approximately 7,750 people worldwide and had revenues exceeding $2.1 billion in 2013. For more information, visit our website at www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Bio-Rad Laboratories, Inc.
312-997-2436 x 112